About the ABPI

The ABPI represents innovative resea​rch-based biopharmaceutical companies, large, medium and small, leading an exciting new era of biosciences in the UK.

Our industry, a major contributor to the economy of the UK, brings life-saving and life-enhancing medicines to patients. We represent companies who supply more than 80 per cent of all branded medicines used by the NHS and who are researching and developing the majority of the current medicines pipeline, ensuring that the UK remains at the forefront of helping patients prevent and overcome disease.

Globally our industry is researching and developing more than 7,000 new medicines.

The ABPI is recognised by government as the industry body negotiating on behalf of the branded pharmaceutical industry for statutory consultation requirements including the pricing scheme for medicines in the UK.​​​​​​​


  1. 'First-choice antidepressant use in adults with depression or generalised anxiety disorder'. Key therapeutic topic [KTT8]. National Institute for Health and Care Excellence (NICE). Published date: January 2015. Last updated: February 2016. Link accessed: July 2017 [https://www.nice.org.uk/advice/ktt8/chapter/evidence-context]​

Media enquiries

+44 (0) 20 7747 7147​​